Heron Therapeutics Inc (NASDAQ:HRTX) a Buy: Brean Capital

In a research note issued to investors, Jonathan Aschoff at Brean Capital Reiterated their Buy rating on Heron Therapeutics Inc (NASDAQ:HRTX). In the year following Aschoff’s ratings, the stocks covered yield an average return of 7.5% according to TipRanks.com. In the past year 104 out of 196 recommendations or 53% were successful.

Wall Street analysts have placed a target price of $26.5 for Heron Therapeutics, Inc. (NASDAQ:HRTX). This number is based on the mean consensus estimate from the 4 research firms that recently issued reports on the stock.

The average broker recommendation is arithmetical average of the individual ratings contributed by sell-side analysts to produce a Consensus Analyst Rating for each stock. On a scale of 1 to 5 where 1 is a Strong Buy and 5 is a Strong Sell, has the stock ranked 1 based on 4 broker recommendations. Of the 4 analysts who have issued estimates, the most bullish sees the stock reaching $40 within the next 12 months while the most conservative sees the stock at $20 within the year.

According to analysts, Heron Therapeutics, Inc. (NASDAQ:HRTX) is expected to report earnings per share for the current fiscal quarter of $-0.65. This is the consensus mean estimate based on the individual covering sell-side analysts’ reported numbers. The company last reported earnings for the period ending on 2015-03-31 of $-0.7. The reported number was -0.06 away from the consensus estimate, or a surprise factor of -9.38 .

In looking at the long term growth prospects of the company, sell-side analysts have a consensus mean earnings per share estimate for the current year of $N/A. The high end estimate for this time frame is $N/A with the low being $N/A.